There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) and Intra-Cellular Therapies (NASDAQ:ITCI) with bullish sentiments.
Biohaven Pharmaceutical Holding Co Ltd (BHVN)
Biohaven Pharmaceutical Holding Co Ltd received a Buy rating and a $55 price target from Cantor Fitzgerald analyst Brandon Folkes today. The company’s shares closed yesterday at $35.62.
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -2.3% and a 44.1% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.
Biohaven Pharmaceutical Holding Co Ltd has an analyst consensus of Strong Buy, with a price target consensus of $46.80, a 31.4% upside from current levels. In a report issued on August 16, Piper Jaffray also reiterated a Buy rating on the stock with a $48 price target.
.
See today’s analyst top recommended stocks >>
Intra-Cellular Therapies (ITCI)
Cantor Fitzgerald analyst William Tanner initiated coverage with a Buy rating on Intra-Cellular Therapies today and set a price target of $32. The company’s shares closed yesterday at $19.97.
According to TipRanks.com, Tanner is a 3-star analyst with an average return of 2.5% and a 46.9% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Aquinox Pharmaceuticals, and Amag Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intra-Cellular Therapies with a $31.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
